Vytrus Biotech continues to grow, one more year. The Catalan company of cosmetic ingredients based on plant biotechnology has made public its audited financial results and closes 2025 with 2.89 million euros.
The company has announced that this 2025 they have increased their sales and that also this increase in revenue has been possible due to the control of operating costs and the decrease by 47% in financial costs.
The company has closed the fiscal year with a turnover that reached 8.37 million, 66% more than the previous year, and an Ebitda of 4.16 million, 106% more year-on-year.
The company's gross financial debt has been reduced by more than 20% and allows the company to have a cash flow position above 1.4 million.
Regarding regions by geographical areas, the European Union continues to be a key area for Vytrus, with an increase of 63%. The United States, for its part, has grown by 39% and the largest growth has been in Asia-Pacific with 114%. Latin America also holds a relevant role for the company, which has increased its purchases from the company by 22%.
Vytrus Biotech announced last October that it will continue to grow thanks to the construction of a new production plant in the Catalan city of Terrassa and that has entailed an investment of 3.5 million euros and this will allow the company to triple its production capacity. The facility will have 1,500 square meters and will be located very close to its offices.